Levemir Innolet

Insulin detemir, the active ingredient in Levemir Innolet, is an insulin analog presented as a clear solution for subcutaneous use. It provides basal insulin coverage to help lower blood glucose levels in patients with diabetes mellitus, both type 1 and type 2.

GNH USA supplies Levemir Innolet as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, adhering to stringent quality standards and providing reliable cold‑chain logistics for injectable products. Our network ensures timely delivery across EU and global markets.

Levemir Innolet, an insulin analog, provides basal insulin support for diabetes management.

Type 1 diabetes mellitus: supplies long‑acting basal insulin to maintain fasting glucose control. Type 2 diabetes mellitus: adds basal insulin when oral agents are insufficient to achieve glycemic targets. Diabetes mellitus requiring basal insulin supplementation: delivers consistent insulin levels to reduce overall hyperglycemia.

Levemir Innolet may be associated with several adverse reactions.

Common Side Effects: - Hypoglycemia: low blood glucose episodes, especially if meals are missed or dosing is excessive. - Injection‑site reactions: redness, swelling, or itching at the injection site. - Weight gain: modest increase in body weight with chronic use. - Lipodystrophy: localized changes in subcutaneous fat. - Edema: mild fluid retention, often peripheral. - Headache: transient mild headaches.

Serious or Rare Side Effects: - Severe hypoglycemia requiring assistance. - Anaphylactic or severe allergic reactions, including rash and angioedema. - Development of insulin antibodies that may alter glucose control. - Hypokalemia: low potassium levels in rare cases. - Necrotizing fasciitis at injection site (extremely rare). - Acute pancreatitis reported in isolated cases.

Before initiating therapy, consider the following precautions.

Monitor blood glucose regularly: adjust dose based on fasting and pre‑meal readings. Renal impairment: reduce dose and monitor for hypoglycemia. Hepatic disease: use with caution; liver dysfunction may affect insulin clearance. Hypoglycemia unawareness: educate patients to recognize early symptoms. Pregnancy and breastfeeding: only use if benefits outweigh potential risks. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Levemir Innolet can interact with several medications.

Major Interactions (Avoid): - Concomitant sulfonylureas or meglitinides: may cause severe hypoglycemia. - Beta‑blockers: can mask hypoglycemia symptoms, making detection difficult.

Moderate Interactions (Monitor Closely): - ACE inhibitors or ARBs: may potentiate insulin’s glucose‑lowering effect. - Thiazide diuretics: can increase blood glucose, requiring dose adjustment. - Corticosteroids: raise glucose levels, possibly necessitating higher insulin doses. - Oral contraceptives: may alter insulin requirements. - Alcohol: can precipitate delayed hypoglycemia, especially with missed meals.